Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Clinical trial NCT07549061 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07549061
- Sponsor
- Shanghai Chest Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-30
- Primary completion
- 2028-05-30
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.